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Abstract
The collection and use of patient health data are central to any kind of activity in the health care system. These data may be
produced during routine clinical processes or obtained directly from the patient using patient-reported outcome (PRO) measures.
Although efficiency and other reasons justify data availability for a range of potentially relevant uses, these data are nearly always
collected for a single specific purpose. The health care literature reflects this narrow scope, and there is limited literature on the
joint use of health data for daily clinical use, clinical research, surveillance, and administrative purposes. The aim of this paper
is to provide a framework for discussing the efficient use of health data with a specific focus on the role of PRO measures. PRO
data may be used at an individual patient level to inform patient care or shared decision making and to tailor care to individual
needs or group-level needs as a complement to health record data, such as that on mortality and readmission, in order to inform
service delivery and measure the real-world effectiveness of treatment. PRO measures may be used either for their own sake, to
provide valuable information from the patient perspective, or as a proxy for clinical data that would otherwise not be feasible to
collect. We introduce a framework to analyze any health care activity that involves health data. The framework consists of four
data processes (patient identification, data collection, data aggregation and data use), further structured into two dichotomous
dimensions in each data process (level: group vs patient; timeframe: ad hoc vs systematic). This framework is used to analyze
various health activities with respect to joint use of data, considering the technical, legal, organizational, and logistical challenges
that characterize each data process. Finally, we propose a model for joint use of health data with data collected during follow-up
as a base. Demands for health data will continue to increase, which will further add to the need for the concerted use and reuse
of PRO data for parallel purposes. Repeated and uncoordinated PRO data collection for the same patient for different purposes
results in misuse of resources for the patient and the health care system as well as reduced response rates owing to questionnaire
fatigue. PRO data can be routinely collected both at the hospital (from inpatients as well as outpatients) and outside of hospital
settings; in primary or social care settings; or in the patient’s home, provided the health informatics infrastructure is in place. In
the future, clinical settings are likely to be a prominent source of PRO data; however, we are also likely to see increased remote
collection of PRO data by patients in their own home (telePRO). Data collection for research and quality surveillance will have
to adapt to this circumstance and adopt complementary data capture methods that take advantage of the utility of PRO data
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collected during daily clinical practice. The European Union’s regulation with respect to the protection of personal data—General
Data Protection Regulation—imposes severe restrictions on the use of health data for parallel purposes, and steps should be taken
to alleviate the consequences while still protecting personal data against misuse.
(J Med Internet Res 2019;21(5):e12412)   doi:10.2196/12412
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Introduction
Health information is central to all types of activities in the
health care system, all of which involve collecting, analyzing,
or using health information [1]. Securing personal data against
misuse is the background for several legal initiatives, for
instance, the implementation of the European Union’s General
Data Protection Regulation (GDPR) [2]. One key element of
this regulation is the principle that personal data collected for
one purpose may not be immediately transferred and used for
other purposes. However, while misuse of personal data poses
a severe ethical problem, so does waste and duplicate collection
of the same data from the same patients due to legal,
organizational, and technical dysfunction. In addition, from the
patient’s perspective, duplicate collection of data may be
unnecessarily burdensome and time consuming, and the
possibilities and advantages of alternative uses of health data
should therefore be considered. We have discussed the patient’s
perspective of joint use in more detail elsewhere [3].
Health information may be generated as an integrated part of
health care activities, such as biochemical variables or entries
in hospitals’ electronic health record (EHR) system, or it can
obtained directly from the patient. The latter is the case for
patient-reported outcome (PRO) measures, which have been
defined by the US Food and Drug Administration as
measurements “of any aspect of a patient’s health that comes
directly from the patient, without interpretation of the patient’s
responses by a physician or anyone else” [4]. This definition
emphasizes the standardization of PRO data as opposed to
unstructured clinician-reported summaries of patient history
contained in the notes in patients’ health records.
The evaluation of treatment outcomes for each individual patient
is typically captured by a combination of biological data,
physical examination, and communication with the patient.
However, evaluations of treatment outcomes at a group level
(defined geographically, administratively, epidemiologically,
or at the facility level) often focus solely on mortality;
readmission; and, if available, data such as medicine use and
other use of health services. Although these outcomes are
undeniably important, they may fail to fully capture treatment
outcomes. PRO measures can be used to complement such data
as a primary or an additional distal outcome, or even serve as
a proxy for an unmeasured clinical variable when collection of
the latter is not feasible [5].
Health informatics aims to respond to the increasing demands
of systematic collection and processing of data to inform
individual patient care, service improvements, and precision
medicine. A lot of effort and resources are expended on
collecting, processing, storing, and retrieving health information
(both PRO measures and other clinical measurements) such as
in hospitals’ EHR systems. In parallel, an increasing number
of research projects and initiatives independently collect health
information for their own specific objectives. Although health
informatics, as a discipline, engages with stakeholders from a
wide range of professional backgrounds, roles, and interests, it
mostly does so with a focus on one specific single application
(clinical practice, clinical research, administrative purposes,
surveillance, or computer science), as evidenced in textbooks
and the relevant literature [1]. As a consequence, there is limited
literature on the joint use of health information for several
purposes.
Technical, legal, organizational, and other types of obstacles to
the availability of data for multiple purposes result in inefficient
use of resources among patients and clinicians as well as in the
health care system and society. Where there is no additional
benefit from repeating a measurement, the same health
information should be collected only once. A typical example
would be laboratory tests, which may be performed by the
family doctor before referral to the hospital, but which may be
repeated, in many circumstances, unnecessarily, once the patient
arrives at the hospital. Similarly, clinicians frequently struggle
to retrieve measurements needed for maintaining quality
registers even though they may already be recorded in the EHR
system. Similarly, PRO measurements may be repeatedly and
independently collected in parallel for different purposes, such
as clinical management, quality surveillance, and research
projects. This may not just mean a waste of resources and an
unnecessary burden to patients, but may also have implications
for data quality, as response fatigue may lead to reduced
response rates.
To qualify the discussion of efficient use of health data, we need
a common language usable for all stakeholders, which does not
exist. The aim of this paper is to propose a framework for
analysis of use and reuse of health information, with a specific
focus on the role of PRO measures in order to initiate and
facilitate a more precise discussion.
Definitions
There is no consensus on the method to define health
information and health data. All definitions rely on the concepts
of information (facts about a situation, person, event, etc [6])
and the organized property of data. Data have been defined
accordingly in various ways such as (1) “any organized
information collected by a researcher” [7], (2) “information or
knowledge represented or coded in some form suitable for better
usage or processing” [8], or (3) “information, especially facts
and numbers, collected to be examined and considered and used
to help decision making” [6]. The first definition focuses on the
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collection process and excludes purposes other than research,
while the second one relies on data structure only. The third
one identifies three processes relevant to the health data:
collection, examination, and use; it furthermore acknowledges
that the nature of data is preserved even if they are only stored
and not used, at least not immediately.
In this paper, we use the third definition and differentiate three
data processes: data collection, data aggregation, and data use.
As patients are the unit of observation for health data, we need
to additionally consider a patient-identification process to define
whose data will be collected. We will focus on persons who
may have, or are under surveillance for, a health condition and
use the term “patient” even though some may not have a medical
diagnosis. A generic model for health data covering any
patient-related health data activity is shown in Figure 1.
Definitions are summarized in Textbox 1.
The patient-identification process corresponds to the definition
of the patient or the group of patients that will be the ultimate
source of data. The subsequent data collection process contains
measurement methods for generating data for that patient or
population of patients as well as logistic issues. In the data
aggregation process, data are transferred, organized, and
transformed to enable their subsequent use. Aggregation may
include data logistic procedures like transmission, data
reformatting, and data management procedures such as
combining and merging with other data. The aggregation may
be explicit during data management (eg, a specific data manager
making the dataset ready for the researcher’s use) or implicit
(eg, such as a clinical summary based on patient data in an
emergency room). In the data use process, the aim for the actual
health data activity is fulfilled (eg, publish the results or a
clinical decision of a treatment plan). Any pair of consecutive
data processes may be repeated and make take place
simultaneously.
Two dimensions can be recognized across all four data
processes: level and timeframe. Level may be either the
individual patient or a defined patient group level (eg, patients
admitted to a hospital department or patients with a specific
health condition). Timeframe considers the scope of the health
data activity and may be either ad hoc or part of a systematic
planned process. Examples are provided below.
Based on these dimensions, 2 × 2 tables with four cells may be
constructed for each of the four processes. Four basic health
data activities may be defined, where the same cell is used in
all the four data processes in Figure 1. Figure 2 shows such
examples.
In most heath data activities, different cells are applied in the
four health data processes, and these patterns will be analyzed
to highlight their properties and differences.
Figure 1. The four data processes in the lifespan of patient-related health data. Patient identification process: Identification of patient(s) from whom
data are to be collected. Data collection process: The actual collection of health data including logistic procedures. Data aggregation process: Management
and organization of collected data for the data use process. Data use process: Use of the health data for the purpose of the specified activity. Each process
may be repeated or may take place simultaneously with the previous process. Further information is provided in Textbox 1.
Textbox 1. Definitions of health data terms.
Health data: Health information about individual patients
Health data activity: An activity with a health-related aim that uses or produces health data
Health data processes: Any health data activity includes four processes:
• Patient identification process: Identification of patient(s) from whom data are to be collected
• Data collection process: The collection of health data
• Data aggregation process: Transfer or organization of health data in a way that enables data use
• Data use process: Use of health data for the purpose of a specified health data activity
Timeframe: The timeframe of a health data process:
• Systematic: A planned or repeated health data process
• Ad hoc: A nonplanned process
Level: The level of a health data process:
• Patient level: The individual patient level
• Group level: A level with patients grouped according to some defined criteria
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Figure 2. Examples of basic health data activities, where the same cell is used in all the four health data processes. I: The patient makes an appointment,
and during the consultation, data are collected and aggregated to make a clinical decision and treatment plan (all four data processes ad hoc at the patient
level). II: The target population is identified and data are collected, managed, analyzed, and published (all data processes ad hoc at a group level). III:
An inpatient is discharged and referred for continuous planned outpatient follow-up and data are collected during follow-up, aggregated at each visit,
and used at the visit (all data processes are systematic at the patient level) IV: Patient groups are identified repeatedly (eg, once a year) based on some
criteria and data are collected, managed, and analyzed/reported (all data processes take place systematic at a group level).
Basic Health Data Activities
Each data process of basic health data activities (Figure 2) is
described below and displayed in Table 1. A description of the
contents of each process is shown in the Multimedia Appendix
1.
The Single-Episode Clinical Contact Activity
The patient makes an appointment with the general practitioner.
During the consultation, data are collected by medical history
and physical examination. These data and a general view of the
patient and his/her resources are aggregated by the general
practitioner into a conclusion and used for a clinical decision.
Another single-episode example is an emergency room visit.
The timeframe for all the four data processes listed in Figure 1
is ad hoc, and all take place at the patient level. The content of
the data collection process may include systematic methods
such as standardized blood tests or use of a specific validated
questionnaire, in which case, the timeframe is ad hoc.
Table 1. Examples of basic and complex health data activities divided by level and timeframe. In basic health data activities, all four processes are in
the same level/timeframe cell.
Data useData aggregationData collectionPatient identificationHealth data process
GroupPatientGroupPatientGroupPatientGroupPatient
SysAd
hoc
SysAd
hoc
SysAd
hoc
SysAd
hoc
SysAd
hoc
SysAd
hoc
SysAd
hoc
SysaAd
hoc
With basic data process patterns
✓b✓b✓b✓bSingle-episode clinical contact
✓b✓b✓b✓bPlanned patient follow-up
✓b✓b✓b✓bClinical research (cross-sectional)
✓b✓b✓b✓bQuality surveillance program
With complex data process patterns
✓b✓b✓b✓bClinical research (cohort)
✓b✓✓b✓b✓✓bClinical guideline
✓b✓b✓b✓b✓✓bIndividual prognosis forecast
✓b✓b✓b✓bScreening program
✓b✓b✓b✓b✓✓Disease surveillance
✓b✓✓b✓✓b✓bHealth care error surveillance
✓✓b✓b✓b✓✓bPrimary health care, traditional
✓✓✓b✓✓✓b✓✓✓b✓✓✓bPrimary health care, new trend
aSys: Systematic or repeated data process.
bThe most frequently applied data processes.
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The Planned Outpatient Follow-Up Activity
Many patients with a chronic disease have systematic follow-ups
in an outpatient clinic. The patients are referred to outpatient
follow-up in a systematic manner based on written formal or
local informal guidelines. The data needed for the outpatient
consultation (eg, medical history, laboratory tests, PRO
measures, and physical examination) are collected, aggregated,
and used at the patient level in relation to each visit. The
timeframe for all the four data processes is systematic and takes
place at the patient level.
The Cross-Sectional Clinical Research Activity
In a cross-sectional study, the group of patients is defined once,
the data are collected and analyzed once, and the results based
on condensed data are published once. Another example is a
registry-based study. The timeframe for all four data processes
is ad hoc and takes place at a group level.
The Quality Surveillance Program Activity
The quality surveillance program is an ongoing activity, where
at a defined timepoint, (eg, once a year), data are sampled and
subsequently analyzed with respect to differences between
departments and hospitals. Reports are published and used for
optimizing quality of care or to inform the patient’s choice of
health care provider. The timeframe for all four data processes
is systematic with predefined intervals and take place at a group
level.
Complex Health Data Activities
Although the abovementioned activities apply data processes
in the same cell in all four data processes, most health data
activities combine different cells. Table 1 (lower part) shows
examples of such activities. The list is not comprehensive but
represents examples of the possible combinations of data process
patterns.
The Longitudinal Clinical Research Activity
The patient-identification process—the recruitment (eg, for a
clinical trial)—takes place once, or in the case of an open cohort
study, systematically over a long inclusion period. Data are
collected systematically over time according to a defined study
protocol. Aggregation (data management and analysis) and use
(publication) take place only once. All data processes are
systematic and take place at a group level. As discussed later,
these data can be used for a range of other purposes.
The Clinical Guideline Activity
Clinical guidelines are based on meta-analyses of clinical trials
and longitudinal studies collected at a group level. Data are
aggregated to inform the guidelines and are published and
implemented once or at regular intervals. The use of clinical
guidelines is, however, most often ad hoc at the individual
patient level when clinical decisions about diagnostic procedures
and treatment are made at the “bedside” together with that
specific patient. In many countries, the traditional ad hoc use
of guidelines is being replaced by quality programs or pay-per
performance systems with the purpose of implementing the
guidelines for all relevant patients. This will move the data use
process from ad hoc to systematic at the patient level.
The Individual Prognosis Activity
Like treatment guidelines, prognostic indicators rely on
information collected at the group level. Prognostic forecasts
are used at the individual patient level and use the experiences
of cohorts of patients to provide information on individual
prognosis. Prognostic information may also be used as decision
support together with the patient, for example, to choose
between two treatments. Two approaches that differ with respect
to the aggregation process—model based or data based—may
be distinguished. In the model-based approach, the data are
aggregated once at the group level and published as, for
example, an equation based on regression coefficients, while
in the data-based approach, data are aggregated from the cohort
data each time the prognosis is asked for, and the prognosis for
a subgroup with characteristics similar to the patient is selected
and displayed [9]. Traditionally, prognosis has been expressed
in terms of clinical outcomes (survival, readmission etc), but
PRO measures may be used to include outcomes such as
symptom burden and functioning.
The Screening Program Activity
In a population screening program, citizens or patients to be
invited are identified systematically based on risk factors such
as age; gender; and at times, disease-specific risk factors. The
data collection takes place at the group level, but the aggregation
and use processes occur at the individual patient level, since
each screening-positive citizen is referred and further diagnosed
and treated individually.
The Disease Surveillance Activity
Registers for monitoring diseases have been known since the
middle of the 19th century, when the first-known registry was
established with the purpose of monitoring leprosy at the
population level [10]. Relevant patients are preferably identified
based on diagnosis codes in existing registers, but a number of
disease registers still rely on reports from the individual
clinician, as do etiological registers like worker’s compensation
registers. Secondary collection of data (eg, histologic type of
cancer or treatment) is organized systematically at the patient
level.
The Health Care Error Surveillance Activity
Health care error is, by nature, an ad hoc event at the patient
level. In surveillance, patients are identified and data are
collected ad hoc at the patient level and aggregated to statistics
and reports at the group level (eg, hospital, department, or
physician). In case of a serious error, the data may also be used
at the individual level as a basis for audit, compensation, or
even legal action.
Activities in Primary Health Care
Traditionally, all four data processes in primary health care have
been ad hoc at the patient level, except for systematic,
group-level programs like vaccination, pregnancy, and maternal
care as well as some mandatory reporting of summary statistics
to medical authorities. However, in some countries, primary
care activities go from ad hoc to systematically framed processes
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at the group level (eg, chronic care programs), where the general
practitioner is expected to identify patients with certain profiles,
and primary health care quality surveillance programs based on
group-level aggregation of clinical data are also being
implemented.
Patient-Reported Outcome Measures in
the Data Collection Process
PRO-based health data are not essentially different from other
sources of information with respect to the data processes of
identification, aggregation, and use, but the data collection
process has a number of features that are specific for PRO
measures. First, without PRO measures, health data on
symptoms and functioning are difficult to collect systematically
and will be limited to observations and unsystematic
clinician-reported subjective summaries of patient history, which
frequently underestimate patient problems [11]. Second, PROs
are often the only way to collect data from a patient at home
(telePRO). A number of telehealth projects have tried to collect
data from home with various hi-tech methods with impact
limited to few specific diseases, whereas telePRO has shown
robustness and been used in a range of chronic diseases [12].
In the following section, PRO-specific aspects of activities listed
in Table 1 will be highlighted.
Patient-Reported Outcome in Patient-Level Activities
Paper-based patient questionnaires have been used in the clinical
setting for decades to support the communication between the
patient and physician. The PRO data are aggregated and used
during the consultation as a tool to screen for a priori defined,
critically important symptoms (red flags) and to prioritize issues
based on the patient’s preferences. This use of PRO measures
has increased with the introduction of Web-based questionnaires,
patient kiosks in the waiting area, etc. The effects on the
consultation processes have been reviewed elsewhere [13-15].
During patient follow-up, PRO data are collected in connection
with each scheduled visit and used to support a longitudinal
overview of symptoms and functions over time and to provide
real-time warnings of deterioration aimed at facilitating a prompt
response from the care team (Figure 3). If patients complete the
PRO remotely online, usually at home (telePRO), this
information may be used as the base for demand-driven
outpatient follow-up without prebooked visits, where
disease-relevant PRO questionnaires filled in at home at fixed
intervals are aggregated by a disease-specific algorithm that
semiautomatically decides whether there is a need or wish for
an outpatient visit [12]. This may solve the paradox that
outpatient clinics may be drowning in patients even though a
substantial part of the visits turn out to be unnecessary from
both the patient’s and clinician’s point of view [16-18]. In
Denmark, this principle has been implemented in chronic and
malignant diseases including asthma, chronic obstructive
pulmonary diseases, epilepsy, sleep apnea, prostatic cancer, and
chemotherapy for a number of malignant diseases [19]. A
national implementation of the principle is underway in
Denmark for selected diagnostic groups.
Figure 3. Longitudinal overview of patient-reported outcome and self-reported measurements in outpatient follow-up (translated from Danish) [13].
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Patient-Reported Outcome in Group-Level Activities
The clinical research, quality surveillance, clinical guideline,
and individual prognosis activities (Table 1) rely on similar data
and will be discussed together. PRO data collection has been
applied for decades in clinical research based on the belief that
outcomes cannot be evaluated on the basis of clinical measures
only. Ideally, most group-based activities need longitudinal data
with a long follow-up period, often beyond the time span of
outpatient follow-up. Due to the increasing use of PRO measures
for clinical purposes, isolated collection becomes problematic
because the patient is often reluctant to answer more than one
questionnaire, especially when the relevance is not clear and
questions across measures overlap, leading to repeated questions
with similar content [20].
The demand for data by the health care system will undoubtedly
increase in the future for all described activities, with the
cross-sectional study as a possible exception. Most of the listed
data-demanding activities focus on longitudinal data, and the
following discussion will focus on this and the role of PRO
measures in a longitudinal follow-up.
Multiple Use of Data Collected as Part of
Clinical Follow-Up
Of the four data processes, the data collection process is the
main challenge with respect to costs as well as logistics. To
reduce costs and workload among patients and clinicians, it is
essential to focus on joint efforts of data collection with
subsequent use in other health data activities. To some extent,
this is already happening (eg, clinical research based on clinical
quality databases).
The basic example of longitudinal activity is the patient
follow-up, where information on the course of treatment,
symptoms, and effect of the intervention is monitored, and, if
necessary, treatment is adjusted. This activity is systematic at
the patient level, and data are already stored for documentation
purposes and may therefore potentially be reused in other
activities. A schematic overview of principles in joint efforts
where data collected from patient follow-up are used in other
activities is shown in Table 2. For the activities listed in Table
1, data aggregation and data use are unchanged; only the
processes in the alternative patient identification and data
collection processes differ.
A model for joint use of health data based on data collected
during patient follow-up with secondary identification of missing
patients, observations, and variables for the alternative use is
shown in Figure 4. The methods used for identification of
missing patients, observations, and variables for the alternative
use (Figure 4) depend on the timeframe of the alternative use.
If the ad hoc method is used, data are exported to an external
system where the completeness is analyzed with record linkage
methods similar to those used in normal registry-based research,
followed by additional ad hoc data collection. If the alternative
use is to take place repeatedly in a systematic manner, this
detection of missing data should preferably take place with
online access to the environment in which the clinical data
reside. In the Central Denmark Region, a central data warehouse
has been established, which now contains clinical information
on medication, diagnoses, and procedures, and more information
is being collected [21]. These data are available for use in
quality-improvement projects, but according to the GDPR, the
use of data for research requires the patient to provide explicit
permission, which reduces the possibility for joint use
significantly.
Table 2. Examples of joint use of health data based on reuse of data routinely collected during patient follow-up with alternative patient identification,
complementary data collection, alternative aggregations, and uses of data.
Data useData aggregationData collectionPatient identificationExamples
GroupPatientGroupPatientGroupPatientGroupPatient
SysAd
hoc
SysAd
hoc
SysAd
hoc
SysAd
hoc
SysAd
hoc
SysAd
hoc
SysAd
hoc
SysaAd
hoc
✓✓BasisBasisc✓bClinical practice
✓✓CompeReused✓Quality surveillance
✓✓CompReuse✓Clinical research
✓✓✓ReuseReuse✓Individual prognosis
aSys: Systematic or repeated data process.
bAll check marks indicate unchanged activity-specific processes (see Table 1).
cBasis: The routine collected follow-up data are the base for alternative uses.
dReuse: Direct reuse of data collected in the cell above.
eComp: Complementary data collection.
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Figure 4. Joint use of health data based on data collected during patient follow-up. The oblique arrow indicates identification of missing patients,
observations, and variables for alternative use.
Group-level ad hoc procedures are applied to identify missing
patients, observations, and variables, with subsequent
complementary data collection. In quality surveillance programs,
identification takes place as a systematic group-level process,
but data collection should rely mainly on data collected as part
of normal clinical activity. In clinical research, the identification
of patients to be included will be ad hoc, based on the specific
research protocol, while data collection should rely on data
collected as part of normal clinical activity as the primary source
of data, supplemented with additional ad hoc data collection,
when supplementary outcome assessment is needed. Individual
prognosis will most often rely solely on data collection in
research activities, but as the only other activity, data-based
individual prognosis may entirely rely on data collected as part
of clinical follow-up, given that the data are available for
instantaneous on-the-fly aggregation and use [9].
Patient-Reported Outcome Data
Collection Supplemental to Data
Collected During Follow-up
Different health data activities may have different data demands
with respect to timing and PRO content, which makes
supplemental PRO data collection necessary. PRO collection
in clinical practice does not cover the whole population of
patients, since some patients may not attend follow-up and some
patients may, for one reason or another, not complete a
questionnaire. For clinical use, response rates over 90% are
obtainable in telePRO [12,22]. For the traditional use of clinical
PRO measures, typically collected in the waiting room area,
PRO data are obtained only from patients who turn up at
follow-up visits, and the response rate is dependent on local
commitment, influenced by local population characteristics and
configuration of the system (user interface, accessibility and
compatibility) and integrated within the existing EHR, clinical
pathways, and workflow.
Clinical data collection stops when the patient follow-up ends.
For reuse in other activities, it may be necessary to apply
supplemental data collection. It is possible to incorporate
supplementary research items into PRO questionnaires used for
clinical purposes as well as to extend the follow-up period longer
than clinically relevant for data use in the activities of clinical
research, quality surveillance, and individual prognosis. With
respect to content, PRO questionnaires used for a clinical
purpose may not be appropriate for other activities, but with
respect to domains to be covered, the common set between the
activities is often substantial. For example, the European
Organisation for Research and Treatment of Cancer scales
created for use at group level are often usable for telePRO [23]
when supplemented with a few items, most importantly, the
patient’s preference for contact with the health care provider.
High response rates are crucial for PRO data collection in any
health data activity, and PRO data collection in clinical practices
often has higher response rates than PRO data collected for use
at group level [22], where the response rate is dependent on
local coordination and commitment [24]. Response rates are
dependent on how relevant the data appear to the patient, and
clinical use seems nearest to the patient. PRO data collected in
clinical practice may therefore yield higher quality of data than
traditional surveillance studies. A known problem when PRO
data are collected at a group level is what to do with alarming
answers, the so-called PRO “alerts” such as high depression
scores or signs of suicidal ideation [25]. This is feasible to deal
with in a clinical setting but is very difficult when collecting
data only for group-level use. While supplemental data
collection of clinical data may be troublesome and expensive
due to several reasons such as extra follow-up visits, PRO data
collection processes may be centralized and automated if the
relevant infrastructure is available [22].
Challenges in Reuse of Patient-Reported
Outcome Data Collected During
Follow-up
In order to achieve the anticipated potential of joint use of PRO
data, some critical challenges should be addressed. The
psychometric requirements may vary depending on the specific
use (eg, level of reliability and sensitivity to change), but other
requirements for the data collection process, such as high
response rate, low attrition rate, and high data completeness,
remain essentially the same regardless of the activity and type
of data. All activities must meet challenges in terms of data
collection logistics and management, and the demands for data
security are typically also identical. Supplemental data collection
requires close cooperation between PRO activities with real-time
access to data, which raises some issues. The challenges are
divided into three types.
Legal Challenges
Legislation issues have a bearing on all four data processes;
therefore, the legal framework has to be precisely specified
before any data collection can begin. Activities with systematic
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data collection may typically benefit from permanent permission
from national data protection agencies, while ad hoc projects
must apply for permission for a specified period. The
fundamental problem is that all approvals are only valid for the
specific activity (eg, quality surveillance or clinical research),
which means that data cannot be used for other activities. The
implementation of the European Union’s regulation with respect
to protection of personal data—GDPR [2]—will make it even
more difficult to use data for other purposes without a specific
consent from each patient. This will have a serious impact on
joint use unless health data are given a differentiated treatment,
such that the requirements for confidentiality can be maintained
and individual approval can be collected in an efficient way (eg,
through some form of umbrella approval process). For
group-level use, analyses of personal data may be performed
on a remote server where the researcher may upload a dataset
and merge it with personal data using a unique personal
identifier. The researcher has access to only aggregated data
such as tables and outputs from statistical analyses [26]. Such
a method of accessing personal data is available in Denmark
and the Netherlands, but for now, few health data such as those
on diagnoses and procedures are available for merging.
Technical Challenges
The principle of supplemental identification and data collection
described above presupposes real-time access to relevant patient
databases in the patient-identification process and in most cases,
in the data collection process. Apart from that, there are
substantial technical issues related to the aggregation process.
Data may be collected and stored, but not available for the
relevant alternative aggregation. A typical example is the quality
surveillance activity, where the needed data may already exist
in the patient’s EHR, but an automated process of extracting
and transporting data is not possible due to inadequate and
incompatible information technology systems or a lack of
relevant expertise. PRO data may already be collected but stored
in a different system or format. A possible solution to the latter
is proposed by the international Health Level Seven standards
for transfer of clinical and administrative data between software
apps used by various health care providers [27]. A special Health
Level Seven section for PRO measures has recently been
adopted.
Challenges Related to Content and Timing of Data
Collection
The need for valid, reliable, and responsive measurement scales
is common for data for any health data activity. For PRO data
collected for making individual clinical decisions, measurement
error is of particular importance. Although scales that have
acceptable psychometric properties at the patient level will
normally also perform well at a group level, the opposite is not
true and the desirable content and length of a PRO questionnaire
are likely to differ between group-level and patient-level
activities. In routine patient follow-up visits, short instruments
are often preferred and procedures that the clinician finds
irrelevant for the actual patient may not be collected as
prescribed (eg, a comprehensive time-consuming test of
performance in a patient who has clinically completely recovered
or a depression score in a patient who is clinically obviously
not depressed). A possible solution to these contradictive
interests may be application of item banks and
computer-adaptive testing, which can achieve high reliability
with the lowest-possible administration burden [28]. Timing of
data collection poses another challenge for joint use, and the
optimal timing of data collection may differ between activities.
Quality surveillance and clinical research may prefer that data
collection follow a fixed scheduled in compliance with a
protocol, while outpatient clinical practice is focused on the
practical arrangement of follow-up, and visits often have to be
postponed for various reasons. Although from a clinician’s
perspective, it might be acceptable that patients who are doing
well cancel their appointments, this may result in devastating
selective attrition in group-level activities. From a resource point
of view and the patient’s perspective, a patient who does not
need or want clinical attention should not go to follow-up visits
just to deliver data for other purposes. A rational approach for
addressing these problems with missing data for the alternative
activity could be a supplemental real-time identification of
patients with missing data combined with collection of PRO
data on proxy variables.
Conclusions
We have introduced a model for health data with four data
processes, each dividable with respect to timeframe and group
level, which distinguishes properties relevant to the discussion
of joint use across different purposes and supports consideration
of the associated organizational and technological challenges.
Based on this, we propose a model for joint use of health data,
with data collected during follow-up as the backbone. In the
future, clinical settings will be a prominent source of PRO data
and data collection for research and quality surveillance will
have to adapt to this circumstance and design ways of
complementary data collection as and when necessary. Demands
for health data will continue to increase, which will further add
to the need for the concerted use and reuse of PRO data for
parallel purposes due to financial, logistical, and ethical reasons.
A number of legal, technical, and organization challenges must
be addressed.
The risk of patients’ information being accessed and used by
people for whom it was not initially intended is real. For
example, the use of health data by private insurance companies
might restrict access to health coverage for vulnerable patients
and those with a precondition. Additionally, access to private
medical information by law enforcement agencies could be a
risk for individuals and society. However, the current legal
restriction on the joint use of health data imposed by the GDPR
makes no distinction between these misuses and the uses
described in this paper. Steps should be taken to alleviate the
current legal restriction on the joint use of health data imposed
by the GDPR while still protecting patient data against misuse.
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